FAQ
|
Site Map
|
Links
|
Contact Us |
Search: |
|
Advanced Search
|
 |
| |
 |
Dear friends,
It is with great pleasure that I welcome you to the website of the Pharmaceutical Services of the Ministry of Health. The content of this website is aimed at health professionals as well as pharmaceutical companies and professional societies. The website includes a broad range of information. This includes details on the organisational structure of the Pharmaceutical Services, access to legislation as well as detailed announcements and press releases relating to medicine safety. In addition, the website also includes application forms for all procedures and services, the price list for medicinal products, the formulary of medicines available at the government hospitals, overnight pharmacies etc. In the website, users may also find information for all Councils and Committees of the Pharmaceutical Services as well as their mandates.
It is worth noting that through the e-services module, users can search for registered medicinal products (with the use of key words) and have access to the Product Information Leaflet and other information such as pack sizes, product content, manufacturers etc. An important novelty foreseen for the near future is the implementation of the option for Marketing Authorisation Holders and other applicants to submit their applications in electronic form through the web portal.
The primary objective of the Pharmaceutical Services is to establish a forum for direct communication with the public, associates and stakeholders via the continuous updating and upgrading of our website. It is our desire that the public has access to all useful information relating to matters within our mandate in order to assure a prompt and high quality service.
We wish you a creative and pleasurable navigation at our web site.
Dr Louis Panayi
Director Pharmaceutical Services
  
| | 
 EMA Press Release - Guidance how to manage clinical trials during COVID-19 (Date: 24/03/2020 - Size: 178,44 Kb)
Cyprus as Reference Member State (Date: 03/01/2020 - Size: 519,88 Kb)
Circular from Medicines Council concerning undertaking the role of Reference Member State for Mutual Recognition/Decentralised Procedures by Cyprus (Date: 12/12/2019 - Size: 591,2 Kb)
CESP compulsory submissions (Date: 27/11/2019 - Size: 4561,87 Kb)
Circular Administrative zero Days MRP (initial wave) (Date: 06/05/2019 - Size: 418,66 Kb)
Letter to stakeholders- List of pharmaceutical products needed (Date: 14/01/2019 - Size: 7516,1 Kb)
Circular for the submission of applications for the renewal of exceptional marketing authorisations (Date: 31/08/2017 - Size: 44,51 Kb)
Announcement concerning electronic application forms (Date: 03/02/2016 - Size: 222,98 Kb)
Announcement concerning CESP submissions (Date: 03/02/2016 - Size: 271,13 Kb)
 Revised application form for issue of an exceptional marketing authorization (Date: 27/03/2015 - Size: 67,97 Kb)
|
|
Remdesivir CMA opinion - press release
(Date: 29/06/2020 / Size: 91,37 Kb)
EMA press release_start of conditional marketing authorisation evaluation
(Date: 11/06/2020 / Size: 104,2 Kb)
EMA communication on anti-hypertensives - update
(Date: 05/06/2020 / Size: 101,6 Kb)
Chloroquine Hydroxychloroquine risks update - communication
(Date: 29/05/2020 / Size: 94,27 Kb)
Remdesivir - expansion of compassionate use
(Date: 12/05/2020 / Size: 89,87 Kb)
Ranitidine_EMA public health communication
(Date: 04/05/2020 / Size: 117,84 Kb)
Press release_EMA rolling review of remdesivir
(Date: 04/05/2020 / Size: 101,97 Kb)
Press release_EMA rolling review of remdesivir
(Date: 04/05/2020 / Size: 101,97 Kb)
risk of serious side effects with chloroquine and hydroxychloroquine
(Date: 24/04/2020 / Size: 92,75 Kb)
COVID ADR reporting
(Date: 24/04/2020 / Size: 98,99 Kb)
|
|